



सत्यमेव जयते

Government of India  
Central Drugs Standard Control Organisation (Headquarter)  
(Directorate General of Health Services)  
FDA Bhavan, ITO, Kotla Road  
New Delhi - 110002 (Delhi)  
Phone No.: 91-11-23216367  
Fax No.: 91-11-23236973  
E-Mail: dci@nic.in

File No. BIO/CT/23/000095

Dated: 20-02-2024

To,

M/s. Genova Biopharmaceuticals Limited,  
T-184 Emcure House Bhosari MIDC  
Pune-411026 (India)

Subject: Application for grant of permission to conduct clinical trial entitled – "A prospective, multi-centre, open label, single-arm, phase I study to evaluate the safety of GBL1204 in patients with neovascular age related macular degeneration" as per Protocol No. GBL1204/2023/01 Version1.1 Dated 19.01.2024- regarding

Ref. No.: Your Application No. BIO/CT04/FF/2023/37966 dated 13.07.2023

Sir,

With reference to your application No. BIO/CT04/FF/2023/37966 dated 13.07.2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019. Further based on your request vide application BIO/CT04/FF/2023/37966 dated 13.07.2023 to allow the use of Bevacizumab Intravitreal Injection 1.25 mg PFS manufactured under CT-11 (201524553 dated 24.11.2020) for clinical trial purpose, this office has no objection to your request to use 40 Bevacizumab Intravitreal Injection 1.25 mg PFS from the remaining 12461 PFS manufactured in GMP facility under CT-11 permission (CT11/BIO/20/000068) in the subject clinical trial.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:  
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:  
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.

- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.
- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.
- (XVIII) Clinical Study report (CSR) shall be submitted to this office after completion of the trial.

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: cn=IN, o=CENTRAL LICENSING AUTHORITY, ou=RAJEEV SINGH RAGHUVANSHI,  
2.5.4.20=80c6216a23e4e1fb8a239774cdeb03c2769041015  
a0554fe67154b765db1cb, postalCode=600034, st=TAMIL  
NADU,  
c=IN, email=rajeev.singh@centrallicensingauthority.gov.in,  
FA12A7M26EA94FAS70112AA19013, cn=RAJEEV SINGH  
RAGHUVANSHI  
RAGHUVANSHI  
Drugs Controller General (India)  
Licensing Authority

Yours faithfully,  
**RAJEEV SINGH**  
**RAGHUVANSHI**

## FORM CT-06

(See rules 22, 25, 26, 29 and 30)

### PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s. Genova Biopharmaceuticals Limited, T-184 Emcure House Bhosari MIDC, Pune-411026 (India) to conduct clinical trial entitled "A prospective, multi-centre, open label, single-arm, phase I study to evaluate the safety of GBL1204 in patients with neovascular age related macular degeneration" as per Protocol No. GBL1204/2023/01 Version 1.1 Dated 19.01.2024 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

4. It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

Place: New Delhi  
Date: 20-Feb-2024

**RAJEEV SINGH**  
(Dr. Rajeev Singh Raghuvanshi)  
**RAGHUVANSHI**  
Drugs Controller General (India)  
Central Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,  
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c276904101  
50666dfe67f64b7654b1cb, postalCode=600034,  
serialNumber=657F5E47D940985D8F03BDC902D0E1FE73  
77A11112A6E02F57011204119A18, cf=RAJEEV SINGH  
RAGHUVANSHI  
Date: 2024.02.20 17:17:34 +05'30'

**Annexure:****Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Bevacizumab Injection 1.25 mg pre-filled syringe (PFS) for intravitreal injection (r-DNA origin)	
Therapeutic class	Anti VEGF	
Dosage form:	One pre-filled syringe contains 3.5 mg bevacizumab in 140 microlitres (25 mg/ml) Delivers a single dose of 1.25 mg/0.05 ml	
Composition:	Each PFS contains:	
	<b>Name of Ingredients</b>	<b>Quantity 3.5 mg bevacizumab in 140 microlitre (25 mg/ml) in PFS</b>
	Bevacizumab, In-house	3.5 mg
	Monobasic Sodium Phosphate Monohydrate IP / BP / Ph. Eur	0.812 mg
	Anhydrous Disodium Hydrogen Phosphate BP / Ph. Eur	0.168 mg
	Trehalose Dihydrate BP / Ph. Eur. / USP	8.40 mg
	Polysorbate 20 I.P. / BP / Ph. Eur. / USP)	0.056 mg
	Water for Injections I.P. / BP / Ph. Eur. / USP	q.s. to 0.140 µl
Indications:	Neovascular age-related macular degeneration	

**Details of clinical trial site:**

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	All India Institute of Medical Sciences, Dr. Rajendra Prasad Centre for Ophthalmic Sciences · All India Institute of Medical Sciences ( AIIMS) · Ansari Nagar · New Delhi –110029	Institute Ethics Committee- All India Institute of Medical Sciences Old OT Block, Room No. 102, AIIMS Hospital Ansari Nagar, Delhi South, New Delhi - 110029 EC Reg. No.: ECR/538/Inst/DL/2014/RR-20	Dr. Vinod Kumar
2.	KR Hospital, Mysore Medical College and Research Institute.Mysore-570001	Institutional Ethics Committee Mysore Medical College and Research Institute and Associated Hospitals KR Hospital Mysore 57000 EC Reg. No :ECR/134/Inst/KA/2013/RR-19	Dr Satish K
3.	Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra 411018	Institutional Ethics Committee- Dr DY Patil Vidyapeeth, Pimpri, Pune EC Reg. No.: ECR/361/Inst/MH/2013/RR-19	Dr Nilesh Balaji Giri
4.	Nandadeep Eye Hospital, Opposite patidar bhavan, Madhavnagar road, Sangli, Maharashtra-416416	IEC-Saishwari Clinic -Hospital for Mental Health Saishwari Clinic -Hospital for Mental Health, Yashwant Co Op Housing Society Sangali Road, Miraj MIRAJ Sangli Maharashtra -416410 EC Reg. No.: ECR/1245/Inst/MH/2019	Dr Sourabh Patwardhan